According to the American Thoracic Society, Coccidioidomycosis (also known as Valley Fever) is an infection usually caused by inhaling the spores (“seeds”) of either Coccidioides immitis or Coccidioides posadasii fungi. These spores are found in the soil in certain geographic areas (called endemic) and get into the air when the soil is disturbed. Coccidioidomycosis cannot be passed from person-to-person.
There are three forms of Coccidioidomycosis i.e. acute pulmonary coccidioidomycosis, chronic pulmonary coccidioidomycosis, and disseminated coccidioidomycosis. Disseminated coccidioidomycosis, is the most severe form of the disease and occurs in about 1% of all cases, usually in people who have a poor immune system or pregnant women. This form can spread to the nervous system, bones, joints or skin. The symptoms of Coccidioidomycosis include fatigue (tiredness), cough, fever, shortness of breath, headache, night sweats, muscle aches or joint pain, rash on upper body or legs, etc.
Coccidioidomycosis can be easily diagnosed by collecting a sample of the patient’s sputum (phlegm), blood or other fluid to find out if the fungus is present. If there is difficulty getting a diagnosis from the sputum or blood, a biopsy of lung tissue or spinal fluid may be needed.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/coccidioidomycosis-market
The Coccidioidomycosis market report also covers emerging drugs, current treatment practices, Coccidioidomycosis market share of the individual therapies, current and forecasted Coccidioidomycosis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Coccidioidomycosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Coccidioidomycosis Market Key Facts
According to the Centers for Disease Control and Prevention, approximately 5-10% of people who get Valley fever will develop serious or long-term problems in their lungs. In 2017, there were 14,364 cases of Valley fever reported to the CDC. Most of these cases were in people who live in Arizona or California. Rates of Valley fever are typically highest among people aged 60 and older.
McCotter et al. conducted a study titled “Update on the Epidemiology of coccidioidomycosis in the United States”, incidence of coccidioidomycosis increases steadily with age, with those over age 70 experiencing the highest rate at 209 cases per 100,000 population while the rate for those between 1 and 4 years of age is 7.7 per 100,000 population.
Key Benefits of Coccidioidomycosis Market Report
-
Coccidioidomycosis market report provides an in-depth analysis of Coccidioidomycosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Coccidioidomycosis market report will help in developing business strategies by understanding the Coccidioidomycosis Market trends & developments, key players and future market competition that will shape and drive the Coccidioidomycosis market in the upcoming years.
-
The Coccidioidomycosis market report covers Coccidioidomycosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Coccidioidomycosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The dynamics of the Coccidioidomycosis market is evolving day by day along with various types of treatment options. Management of patients diagnosed with coccidioidomycosis depends on the extent of infection and assessing host factors that predispose to disease severity. People who develop symptoms from Coccidioidomycosis do not require any treatment because symptoms are mild and go away in a few days to few weeks. If symptoms last for more than six weeks which are severe then the treatment is required. Currently, the treatment paradigm for Coccidioidomycosis includes antifungal drugs or intravenous formulations.
Coccidioidomycosis Market Size is anticipated to Increase for the study period, 2017–2030 in the seven markets. The increase in Market Size is a direct consequence of rising incident population and upcoming therapies in the forecast years in the 7MM.
The Coccidioidomycosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Coccidioidomycosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Coccidioidomycosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Coccidioidomycosis Epidemiology
The Coccidioidomycosis epidemiology section covers insights about historical and current Coccidioidomycosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Coccidioidomycosis Drugs Uptake and Key Market Players
The Coccidioidomycosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Coccidioidomycosis market or expected to get launched in the market during the study period. The analysis covers Coccidioidomycosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Coccidioidomycosis market is anticipated to change in the coming years owing to the improvement in the research and development undertaking. There are several key players involved in developing the therapies for coccidioidomycosis.
Some of the key companies in the Coccidioidomycosis market includes:
Scynexis
Mycovia Pharmaceuticals
Amplyx Pharmaceuticals
F2G
Leadiant Biosciences
Janssen Pharmaceuticals
And many others.
Drugs Covered
Ibrexafungerp
VT-1598
Fosmanogepix
Olorofim
Abelcet (Amphotericin B)
Nizoral (Ketoconazole)
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Coccidioidomycosis Competitive Intelligence Analysis
4. Coccidioidomycosis Market Overview at a Glance
5. Coccidioidomycosis Disease Background and Overview
6. Coccidioidomycosis Patient Journey
7. Coccidioidomycosis Epidemiology and Patient Population
8. Coccidioidomycosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Coccidioidomycosis Unmet Needs
10. Key Endpoints of Coccidioidomycosis Treatment
11. Coccidioidomycosis Marketed Products
12. Coccidioidomycosis Emerging Therapies
13. Coccidioidomycosis Seven Major Market Analysis
14. Attribute Analysis
15. Coccidioidomycosis Market Outlook (7 major markets)
16. Coccidioidomycosis Access and Reimbursement Overview
17. KOL Views on the Coccidioidomycosis Market.
18. Coccidioidomycosis Market Drivers
19. Coccidioidomycosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Related Reports
Coccidioidomycosis Epidemiology Forecast to 2030
DelveInsight’s Coccidioidomycosis Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Coccidioidomycosis? in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Coccidioidomycosis Pipeline Insights, 2020
Coccidioidomycosis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Coccidioidomycosis market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/